doi: 10.1001/jama.2020.21749
Frequently Asked Questions How does mazdutide compare to survodutide, since both are GLP-1/glucagon dual agonists
Indeed, the experience of several randomized control trials has been included in the most recent guidelines ( In patients with T2DM, the treatment with SGLT2-i has been associated with a reduction in hospitalization for heart failure and cardiovascular deaths, regardless of pre-existing cardiovascular disease ( Several studies ( This heterogeneity in CV benefits across the trials, also among studies in which drugs of the same class have been used, could be explained by different study designs (i.e
However, clinical decisions about dose interruptions due to surgery, illness, or adverse effects should follow FDA labeling and clinical practice guidelines rather than relying on estimated drug levels from plotters
If your insurance is more likely to cover one medication over another, that becomes the practical choice
Medical Disclaimer: Retatrutide is an investigational compound and is not FDA-approved
